PharmacoEconomics & Outcomes News

, Volume 813, Issue 1, pp 31–31 | Cite as

Tisagenlecleucel in paediatric ALL: cost effectiveness uncertain

Clinical study


  1. Lin JK, et al. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology : 13 Sep 2018. Available from: URL:

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations